Bupropion

Bupropion is an atypical antidepressant. It acts as a norepinephrine–dopamine reuptake inhibitor and a nicotinic receptor antagonist. Common side effects of bupropion include a dry mouth, difficulty sleeping, agitation, and headaches. Serious side effects include an increased risk for epileptic seizures and suicide.

About Bupropion in brief

Bupropion is an atypical antidepressant. It acts as a norepinephrine–dopamine reuptake inhibitor and a nicotinic receptor antagonist. Common side effects of bupropion include a dry mouth, difficulty sleeping, agitation, and headaches. Serious side effects include an increased risk for epileptic seizures and suicide. It is unclear if its use during pregnancy or breastfeeding is safe. In 2018, it was the 26th most commonly prescribed medication in the United States, with more than 24 million prescriptions. The addition of bu Propion to an SSRI may result in an improvement in some people who have an incomplete response to first-line SSRI antidepressants. The effectiveness of buPropion for maintaining abstinence from smoking decreases over time, with 20% of persons remaining abstinent from smoking at one year compared to 6% one year earlier. The U.S. Food and Drug Administration granted approval for marketing of bu propion for the treatment of ADHD in 2007. In Australia and the UK, the only licensed use of the bupropions is for smoking cessation. The American Academy of Child and Adolescent Psychiatry notes that low doses augment nicotine-administration and high doses attenuate it. In the US, the FDA granted approval in 2007 for the use of bu progpropion for self-esteem and self-medication of ADHD. It was approved in 2006 for the prevention of seasonal affective disorder (SAD) In some countries, depression treatment and SAD prevention are off-label uses.

A 2018 meta-analysis found only weak evidence supporting use of Bupropions for depression, with only a few available trials; and the little evidence that was available showed that bupropION had a weak antidepressant effect. A 2016 meta- analysis found that bu Propions is superior to placebo. In depressed people who experience symptoms of sleepiness and fatigue, bu Proponsion has been found to be more effective than selective serotonin reuptakes inhibitors (SSRIs) in alleviating these symptoms. There appears to be a modest advantage for the SSRIs over bu Propension in the Treatment of Anxious Depression (TTD) in the treatment of anxious depression. Buppropion reduces the severity of nicotine cravings and withdrawal symptoms. It increases the likelihood of quitting smoking by approximately 1 to 6 fold, but less effective than varenicline to nicotine replacement therapy (Varenicicline) Animal studies indicate that administration of buropion at less than the therapeutic dose may actually enhance the rewarding properties of nicotine, i.e. it may actually be more rewarding than the recommended therapeutic dose of Varenicine. It has been shown to be effective in preventing the recurrence of SAD in children and adolescents. In 2006, the U. S. FDA granted the FDA approval for use in SAD. in 2006, for the Prevention of Seasonal Affective Disorder (SAD) It was originally called by the generic name amfebutamone, before being renamed in 2000.

Related posts:

Food and Drug Administration Emergency use authorization Anti-tobacco movement in Nazi Germany Coeliac disease